AbbVie Inc. (ABBV) News
Filter ABBV News Items
ABBV News Results
|Loading, please wait...|
ABBV News Highlights
- ABBV's 30 day story count now stands at 20.
- Over the past 6 days, the trend for ABBV's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
- DRUG, PEAK and MG are the most mentioned tickers in articles about ABBV.
Latest ABBV News From Around the Web
Below are the latest news stories about ABBVIE INC that investors may wish to consider to help them evaluate ABBV as an investment opportunity.
A little-known group of Buffett stocks includes three members of dividend royalty with solid growth prospects.
With a price-to-earnings (or "P/E") ratio of 20.1x AbbVie Inc. ( NYSE:ABBV ) may be sending bearish signals at the...
Drugmaker AbbVie (NYSE: ABBV) is one of the largest healthcare stocks in the world, with a market cap of over $250 billion. AbbVie last reported its earnings in July. Humira remains key to AbbVie's business for now, generating $5.4 billion this past quarter, nearly three times the $1.8 billion Skyrizi and Rinvoq generated.
From biotech to managed care, companies are tackling new challenges in science and business. Our healthcare roundtable experts pick 12 stocks that could win.
Let's look at two biotech stocks that look attractive at current levels: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD). AbbVie is one of the largest pharmaceutical companies around. Like other drugmakers, AbbVie benefits from the fact that doctors do not stop prescribing lifesaving drugs even during challenging economic times, nor do patients stop taking them.
As one of the world's largest pharmaceutical companies, it's no surprise to hear that AbbVie (NYSE: ABBV) has plenty of moving parts for investors to think about when they're wondering what to do to make the most money from their shares. AbbVie develops new medicines as its core business, and to make money from doing so, it needs to perform clinical trials to show regulators at the Food and Drug Administration (FDA) that its drugs are both safe and effective. For example, if you buy shares right when everyone is hyped about some recently published clinical trial results, you'll be jumping on the bandwagon right when a ticket is the most expensive.
AbbVie recently submitted a regulatory application in the European Union for Rinvoq to treat patients with a form of inflammatory bowel disease.
The Forces of Beauty® Report from The DREAM Initiative® Reveals Demand for New Standards of Beauty and Imagery
Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), and skinbetter science® announce a new report from their DREAM (Driving Racial Equity in Aesthetic Medicine) Initiative®, along with a long-term partnership with Shutterstock Studios. The report, titled Forces of Beauty®, provides a new understanding of what inclusive and representative beauty looks like today by shedding light on how narrowly defined Eurocentric ideals continue to impact women of color. By surveying over 4,000 women ag
One good way to start your search is by looking at Dividend Kings. AbbVie (NYSE: ABBV) sells the biggest blockbuster of all time. AbbVie's two other immunology drugs -- Skyrizi and Rinvoq -- together are set to eventually surpass peak sales of Humira.
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.